Cardinal Health, Inc. CAH

Even though Cardinal Health (currently trading at $220.37 per share) has gained 6.8% over the last six months, it has lagged the S&P 500’s 22.1% return during that period. This may have investors wondering how to approach the situation.

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

McKesson (MCK) is back in focus after its share price dipped 1.2%, trailing the broader market, as investors weigh mixed earnings estimates against the company’s raised full-year adjusted EPS guidance and specialty-led healthcare footprint. Recent trading has been choppy for McKesson, with the share price slipping 3.95% over the past 30 days even after a 13.86% 90 day share price return and a 5.58% share price gain year to date. That near term hesitation sits against a much stronger backdrop,...

Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

Cardinal Health has been a powerful performer over the past several years. The question now is whether the current share price lines up with what the business is earning. With the stock pulling back slightly in the short term after a strong multi year run, investors are increasingly focused on what its earnings actually justify. Cardinal Health has returned about 378.2% over the past 5 years, which puts real pressure on the current valuation story to be supported by the earnings profile. The...

Profiles 3M, Medline, Cardinal Health, Medtronic and DuPont, covering competitors, segments, regional shares, trends and opportunities. Medical Textile Market Medical Textile Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Medical Textile Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Medical Textile Market to Reach $64.28 Billion by 2030 as Healthcare Demand Accelerates The global medical textile market is experiencing exponential growth, supported by rising

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses. Speaking at the Morgan Stanley Global Heal

Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Offi